Natural Products: A Potential New Hope to Defeat Post-acute Sequelae of COVID-19

Author:

Zhao Shuang1,Abdurehim Aliya1,Yuan Yu1,Yang Tan1,Li Chao1,Zhang Yanqing2,Li Yaxin3,Sun Xiuyan1,Xie Junbo1

Affiliation:

1. College of Traditional Chinese Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People’s Republic of China

2. College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, 300134, People’s Republic of China

3. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City, NY, 10065, United States

Abstract

Abstract: The COVID-19 pandemic was the most significant public healthcare crisis worldwide. It was estimated that 80% of infected patients with COVID-19 have not fully recovered and devel-oped one or more long-term symptoms, referred to as post-acute sequelae of COVID-19 (PASC). Seeking a treatment strategy for PASC has become a concerning topic since the sequelae can cause irreversible multiple organ damage and can severely compromise quality of life. It is indicated that PASC may be closely related to lung injury-induced hypoxia, excessive immune response, cytokine storm, gut bacteria imbalance, and endothelial dysfunction. Also, more and more research has indi-cated that angiotensin-converting enzyme 2 (ACE2) receptor, transient receptor potential ankyrin 1 and vanillin 1 (TRPA1/V1), and nuclear factor erythroid 2-related factor 2 (Nrf2) can be considered as the targets to treat PASC. There is currently still no proven medication for PASC due to its com-plexity. Many clinical practices and studies have shown that natural products have great potential in preventing and treating PASC. Therefore, we intended to provide a comprehensive review of the current literature on PASC and the role of natural ingredients in PASC management. Meanwhile, this review provided meaningful insight for further study of natural ingredients to improve PASC and its clinical application.

Funder

National Natural Science Foundation of China

Tianjin "131" innovative talent team

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference161 articles.

1. World health organization. Coronavirus disease (COVID 19) weekly 271 epidemiological update and monthly operational updates. Available at: ((Accessed on: June 2 7, 2023).

2. Wang H.; Paulson K.R.; Pease S.A.; Watson S.; Comfort H.; Zheng P.; Aravkin A.Y.; Bisignano C.; Barber R.M.; Alam T.; Fuller J.E.; May E.A.; Jones D.P.; Frisch M.E.; Abbafati C.; Adolph C.; Allorant A.; Amlag J.O.; Bang-Jensen B.; Bertolacci G.J.; Bloom S.S.; Carter A.; Castro E.; Chakrabarti S.; Chattopadhyay J.; Cogen R.M.; Collins J.K.; Cooperrider K.; Dai X.; Dangel W.J.; Daoud F.; Dapper C.; Deen A.; Duncan B.B.; Erickson M.; Ewald S.B.; Fedosseeva T.; Ferrari A.J.; Frostad J.J.; Fullman N.; Gallagher J.; Gamkrelidze A.; Guo G.; He J.; Helak M.; Henry N.J.; Hulland E.N.; Huntley B.M.; Kereselidze M.; Lazzar-Atwood A.; LeGrand K.E.; Lindstrom A.; Linebarger E.; Lotufo P.A.; Lozano R.; Magistro B.; Malta D.C.; Månsson J.; Mantilla Herrera A.M.; Marinho F.; Mirkuzie A.H.; Misganaw A.T.; Monasta L.; Naik P.; Nomura S.; O’Brien E.G.; O’Halloran J.K.; Olana L.T.; Ostroff S.M.; Penberthy L.; Reiner R.C.; Reinke G.; Ribeiro A.L.P.; Santomauro D.F.; Schmidt M.I.; Shaw D.H.; Sheena B.S.; Sholokhov A.; Skhvitaridze N.; Sorensen R.J.D.; Spurlock E.E.; Syailendrawati R.; Topor-Madry R.; Troeger C.E.; Walcott R.; Walker A.; Wiysonge C.S.; Worku N.A.; Zigler B.; Pigott D.M.; Naghavi M.; Mokdad A.H.; Lim S.S.; Hay S.I.; Gakidou E.; Murray C.J.L.; Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–21. Lancet 2022,399(10334),1513-1536

3. Raman B.; Bluemke D.A.; Lüscher T.F.; Neubauer S.; Long COVID: Post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J 2022,43(11),1157-1172

4. Choutka J.; Jansari V.; Hornig M.; Iwasaki A.; Unexplained post-acute infection syndromes. Nat Med 2022,28(5),911-923

5. Nolen L.T.; Mukerji S.S.; Mejia N.I.; Post-acute neurological consequences of COVID-19: An unequal burden. Nat Med 2022,28(1),20-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3